Clinical trials: Postmenopause
Postmenopausal Period, Osteoporosis, Postmenopausal
Angeliq Regulatory Post Marketing Surveillance
Angeliq regulatory Post-Marketing Surveillance (PMS) is to get data about safety and efficacy in real practice for the indication approved by Korea Food and Drug Administration (KFDA).
- Trial name
- Angeliq rPMS (NCT01064453)
- Testing
- E2/DRSP (Angeliq, BAY86-4891)
- Where
- South Korea
- Volunteers
- 4,078 people
- Sponsor
- Bayer
Postmenopause
Effects of Wellnara on Climacteric Symptoms
Aim of this NIS is to obtain further information on efficacy, tolerability, and acceptance of Wellnara in a large user population under the conditions of routine medical practice.
- Trial name
- NCT00913926
- Testing
- E2/LNG oral (Wellnara, BAY86-5029)
- Where
- Germany
- Volunteers
- 749 people
- Sponsor
- Bayer